'Despite assurance from China, none of the companies have received supplies from Chinese sellers.'
As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.
'Given the lag in transmission, further softening of lending rates may happen in the coming months.'
'The statistical confidence bands of the fan charts of the forecasts will provide a better sense of the potential variability of outcomes.'
Uncertainties over the impact of the United States' (US') tariffs on India, along with the ongoing transmission of past rate cuts, prompted the members of the Reserve Bank of India's Monetary Policy Committee (MPC) to maintain the status quo during the August meeting, the minutes showed. While some of the external members highlighted their concern over growth, the internal members cited the one-year headline inflation rate overshooting the 4 per cent target.
If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.
Bad loans in the agriculture sector remain elevated, with several public-sector banks (PSBs) reporting higher slippages in the April-June quarter of FY26. For many banks, non-performing assets (NPAs) in farm lending were 5 per cent or more, with some nearing double digits.'
India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.
Shailesh Jejurikar has 'always made an effort to stay close to his roots.'
Analysts believe Tesla will first focus on building the Model Y brand before expanding -- both in terms of volume and models.
The National Pharmaceutical Pricing Authority will monitor how companies are increasing prices of non-scheduled drugs.
In her letter to the Sona BLW board, Rani Kapur said documents executed by her at a time of "mental and emotional vulnerability" were being misused.
'India is a big market for StanC, and it is also fastest growing economy in the world.'
Despite the benefits of hybrid technology, a lack of government backing and few launches have kept the segment from gaining ground.
'India has the potential to grow at more than 7%, with the monetary policy providing a supportive hand.'
'The reported deal between the European Union and China should mitigate it (shortage) for the medium to long term. Let's wait and watch how this plays out.'
'Deposit and lending rates have started to fall considerably. It is likely to spur investment and consumption of durables.'
The share of EVs in the luxury segment rose from 7 per cent in January-May 2024 to 11 per cent during the same period in 2025, marking a 66 per cent growth in the electric luxury segment.
Large tariffs by the United States administration and elevated geopolitical risk have increased near-term global financial stability risks, and along with weather events pose downside risks to domestic growth, Reserve Bank of India (RBI) Governor Sanjay Malhotra said in the foreword to the Financial Stability Report released on Monday.
Skoda India sees growth in automatics and network expansion as key drivers to reach 3 per cent market share, with EV plans and a new SUV also in the works.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances